Patent ID: 7988965
Filing Date: 2011-08-02
Classification: A01K,A61K,A61P,C07K

Abstract:
1. A method of treating systemic lupus erythematosus in a subject, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) a human monoclonal antibody or portion thereof that binds to human AILIM, wherein: (a) a V region DNA encoding a heavy chain variable region of the human monoclonal antibody or portion thereof is from human immunoglobulin heavy chain V gene segment 1-02 or 3-13; (b) a V region DNA encoding a light chain variable region of the human monoclonal antibody or portion thereof is from human immunoglobulin light chain V gene segment L5 or A27; or (c) a V region DNA encoding a heavy chain variable region of the human monoclonal antibody or portion thereof is from human immunoglobulin heavy chain V gene segment 1-02 or 3-13, and a V region DNA encoding a light chain variable region of the human monoclonal antibody or portion thereof is from human immunoglobulin light chain V gene segment L5 or A27.